Application

Analytes: GM-CSF, sCD137, IFNγ, sFas, sFasL, Granzyme A, Granzyme B, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, MIP-1α, MIP-1β, TNF-α, Perforin Recommended Sample type: serum, plasma or tissue/cell lysate and culture supernatant Recommended Sample dilution: Neat Assay Run Time: Overnight Research Category: Inflammation & Immunology

General description

CD8+ T cells (also known as cytotoxic T cells, cytolytic T cells and killer T cells) belong to a sub-group of T cells capable of inducing the death of infected somatic or tumor cells. T cells that bind weakly to Major Histocompatibility Complex (MHC) self-antigens are positively selected into single-positive CD4+ or CD8+ T cells in the thymus. Those CD8+ T cells that survive and mature after activation become cytotoxic cells, expressing T-cell receptors (TCRs) capable of recognizing specific antigenic peptides bound to Class I MHC molecules and the glycoprotein CD8. Affinity between the CD8 protein and the MHC molecule helps to keep the cytotoxic T cell and target closely bound during antigen specific activation. Once activated, CD8+ T cells are generally classified as having a predefined cytotoxic role within the immune system and undergo IL-2 induced clonal expansion, which increases the number of cells specific for the target antigen. The CD8+ T cells then travel throughout the body in search of antigen-positive somatic/tumor cells. The Luminex^® xMAP^® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume. Panel Type: Cytokines/Chemokines

Legal Information

xMAP is a registered trademark of Luminex Corp

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Sensitivity: Refer to kit protocol for sensitivities of individual biomarkers.